CSA Medical, Inc. Selected to Present at Mid-Atlantic Bio Conference

BALTIMORE, Oct. 28 /PRNewswire/ --CSA Medical, Inc. (www.CSAmedical.com) has been selected to present the company's technology and business plans for its proprietary spray cryotherapy platform at the Mid-Atlantic Bio Conference. CSA Medical will be one of only eleven companies presenting in the emerging growth category. Twenty five companies in total will present across three categories. More than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather at the Mid-Atlantic Bio conference at the North Bethesda Marriott Convention Center in Bethesda, MD. CSA Medical will present on Thursday, October 28th at 2:20 pm when company executives, Ric Hughen and Steve Schaefer, will be on hand to present financial highlights, new product development and ongoing commercialization plans for CSA Medical's novel Spray Cryotherapy technology.

CSA Medical is first to harness the power of extreme cold, liquid nitrogen (-196 C), therapeutic energy delivery inside the body. This unique technology (device, catheter and agent) allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body.

"We are thrilled to be selected as this conference is hosted by some of the region's most influential bioscience and investor associations, including the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO)," said Steve Schaefer, the company's President and CFO. "This is quite an honor and reflects strong progress that the company has made gaining customers, treating over 6,000 patients and freezing disease."

The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org.

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to freeze and destroy a wide range of unwanted tissues via an endoscope. Please visit www.CSAmedical.com for more information.

SOURCE CSA Medical, Inc.